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Abstract
OBJECTIVE—One-dose varicella vaccination for children was introduced in the United States in 
1995. In 2006, a second dose was recommended to further decrease varicella disease and 
outbreaks. We describe the impact of the 2-dose vaccination program on varicella incidence, 
severity, and outbreaks in 2 varicella active surveillance areas.
METHODS—We examined varicella incidence rates and disease characteristics in Antelope 
Valley (AV), CA, and West Philadelphia, PA, and varicella outbreak characteristics in AV during 
1995–2010.
RESULTS—In 2010, varicella incidence was 0.3 cases per 1000 population in AV and 0.1 cases 
per 1000 population in West Philadelphia: 76% and 67% declines, respectively, since 2006 and 
98% declines in both sites since 1995; incidence declined in all age groups during 2006–2010. 
From 2006–2010, 61.7% of case patients in both surveillance areas had been vaccinated with 1 
dose of varicella vaccine and 7.5% with 2 doses. Most vaccinated case patients had <50 lesions 
with no statistically significant differences among 1- and 2-dose cases (62.8% and 70.3%, 
respectively). Varicella-related hospitalizations during 2006–2010 declined >40% compared with 
2002–2005 and >85% compared with 1995–1998. Twelve varicella outbreaks occurred in AV 
during 2007–2010, compared with 47 during 2003–2006 and 236 during 1995–1998 (P < .01).
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CONCLUSIONS—Varicella incidence, hospitalizations, and outbreaks in 2 active surveillance 
areas declined substantially during the first 5 years of the 2-dose varicella vaccination program. 
Declines in incidence across all ages, including infants who are not eligible for varicella 
vaccination, and adults, in whom vaccination levels are low, provide evidence of the benefit of 
high levels of immunity in the population.
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Before the introduction of varicella vaccine in the United States in 1995, there were an 
estimated 4 million cases of varicella, 10 000 varicella-related hospitalizations, and 100 
deaths annually.1–4 During the 1-dose varicella vaccination era (1995–2005), varicella 
incidence, deaths, and hospitalizations declined by 90%, 88%, and >65% respectively.5–7
Despite dramatic declines in varicella incidence and severe disease, varicella outbreaks 
continued to occur in highly vaccinated school populations. In 2006, based on disease 
epidemiology during the 1-dose varicella vaccination program, including outbreaks among 
highly vaccinated school populations, immune response to vaccination, and vaccine 
effectiveness, the Advisory Committee on Immunization Practices recommended a routine 
second dose of varicella vaccine for all children.8 We used data from 2 varicella active 
surveillance areas from 1995 to 2010 to describe the impact of the 2-dose varicella 
vaccination program on varicella incidence, disease characteristics, and outbreaks.
METHODS
Active surveillance for varicella was conducted in Antelope Valley (AV), CA, and West 
Philadelphia (WP), PA, from 1995 to 2010 with funding from the Centers for Disease 
Control and Prevention (CDC) by County of Los Angeles Department of Public Health and 
Philadelphia Department of Public Health, as described previously.5,9–12 AV, a 
geographically defined health services district ~70 miles outside the city of Los Angeles, 
had a population of 373 098 in 2010, of which 42% were white non-Hispanic and 40% were 
white Hispanic. WP, an inner-city area of Philadelphia, had a population of 272 260 in 2010, 
of whom 74% were African American. The populations of the 2 surveillance areas were 
disproportionately African American and Hispanic compared with the overall US population 
in 2010 (13.6% African American, 16.3% Hispanic).13
A varicella case was defined as an illness characterized by acute onset of a generalized 
maculopapulovesicular rash without other known cause.14 One-dose breakthrough varicella 
was defined as a varicella case in a person >1 year of age vaccinated with 1 dose of varicella 
vaccine >42 days before onset of rash. Two-dose breakthrough varicella was defined as a 
varicella case in a person >1 year of age vaccinated with 2 doses of varicella vaccine, with 
the second dose received >42 days before rash onset. A varicella outbreak was defined as ≥5 
cases of varicella from a common setting, epidemiologically linked, and occurring within ≥1 
incubation periods (ie, ≥21 days) of another case. In 2010, there were 263 reporting sites in 
AV and 330 in WP. Reporting sites included schools, day cares, health care providers, 
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hospitals, public health clinics, correctional facilities, and homeless shelters. Reporting sites 
reported biweekly, even when no cases were identified. Sites that failed to report biweekly 
were contacted to verify the absence of cases. Surveillance staff conducted case 
investigations with each case patient or parent/guardian to collect demographic, clinical, and 
epidemiologic data through a structured telephone interview. Medical records were reviewed 
for all serious varicella-related complications or hospitalizations. Immunocompromising 
conditions were defined as “chronic medical conditions that depress the immune system (eg, 
cancer, leukemia, HIV/AIDS, organ transplant).” Vaccination status was verified by using 
vaccination registries and school or provider records.
National Immunization Survey results from Los Angeles County and Philadelphia County 
were used to estimate 1-dose varicella vaccination coverage among children 19 to 35 months 
of age in AV and WP during 2006–2010.15,16 Because the National Immunization Survey 
does not capture 2-dose varicella vaccination coverage, a variety of data sources were used 
to derive estimates of 2-dose varicella vaccination coverage. In AV, 2-dose varicella 
vaccination data were obtained from health forms completed by parents or guardians of 
kindergarten students who entered an AV public school district during the 2009–2010 
school year, similar to methods used by CDC to annually analyze school vaccination 
coverage data from federally funded immunization programs.17 Two-dose varicella 
vaccination coverage among Kaiser Permanente Southern California enrollees aged 4 to 6 
years who represented ~20% of the insured population residing in AV was determined using 
the Kaiser Immunization Tracking System using methods described previously.18 Two-dose 
varicella vaccination data were extracted from the Philadelphia Department of Public 
Health’s Kids Immunization Database/Tracking System for children aged 4 to 12 years 
living in WP who had ≥1 vaccinations of any type recorded.
SAS (version 9.2; SAS Institute, Cary, NC) was used for data analysis. We calculated 
incidence rates of reported varicella per 1000 population using population estimates from 
the US Census Bureau. We used Poisson regression to estimate the annual trend in age-
specific incidence rates over the periods from 1995, the year varicella vaccine was 
introduced, and 2006, the last full year of the 1-dose vaccination program, to 2010, the 
fourth full year of the routine 2-dose varicella vaccination program for children in the 
United States.
RESULTS
There were 1528 cases reported from 2006 to 2010, 1183 from AV and 345 from WP; 145 
(9.5%) were laboratory confirmed. From 2006 to 2010, varicella incidence declined by 
76.3% in WP (P < .001) and 67.1% in AV (P < .001; Fig 1). Age-specific varicella 
incidence rates declined 81.3% to 98.7% during 1995–2010 (P < .001) and were lower for 
all age groups in 2010 compared with 2006 (Table 1).
Of the 1302 (89.7%) case patients ≥1 year of age from AV and WP during 2006–2010 with 
information on vaccination status, 61.7% had received 1 dose of varicella vaccine and 7.5% 
2 doses. Although the overall proportion of case patients with ≥1 doses of varicella vaccine 
did not vary significantly during 2006–2010, the proportion among case patients 10–14 and 
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15–19 years of age increased from 56.2% to 92.3% and 11.1% to 31.6%, respectively. 
Among vaccinated case patients 4 to 14 years of age, the proportion that had received 2 
doses of varicella vaccine increased from 0.9% in 2006 to 43.4% in 2010. The median age 
among vaccinated case patients in AV increased from 8 years in 2006 to 9 years in 2010 and 
from 6 years in 2006 to 7 years in 2010 in WP. Among unvaccinated case patients, the 
median age in AV increased from 12 years in 2006 to 16 years in 2010 and from 15 years in 
2006 to 20 years in 2010 in WP.
Information on vaccination status and number of lesions was available for 1216 (83.8%) 
case patients ≥1 year of age during 2006–2010 (Table 2). Among those ≥4 years of age, 
there were no statistically significant differences in the proportions by number of lesions 
comparing 1- to 2-dose breakthrough case patients within age groups or comparing age 
groups within 1- and 2-dose vaccination-status categories.
A smaller proportion of the case patients reported during 2006–2010 had 
immunocompromising conditions compared with 1995–2005 (0.4% vs 11.7% for 0- to 14-
year-olds, 0% vs 13.7% for 15- to 19-year-olds, and 3.6% vs 13.6% for ≥20-year-olds, 
respectively, P < .01 for all 3 age groups). A larger proportion of the adolescent and adult 
case patients reported during 2006–2010 received antiviral treatment of varicella compared 
with during 1995–2005 (26.8% vs 16.7% for 15- to 19-year-olds and 59.6% vs 26.1% for 
≥20- year-olds, respectively, P < .01 for both age groups).
During 2006–2010, there were 3 varicella-related hospitalizations in AV and 7 in WP for 
varicella-related hospitalization rates of 0.17 per 100 000 population (95% confidence 
interval 0.05–0.51) in AV and 0.52 per 100 000 population (95% confidence interval 0.25–
1.10) in WP. This represents declines in varicella-related hospitalizations of 43.3% and 
92.2% in AV compared with 2002–2005 and 1995–1998, respectively, and 47.4% and 
86.8% in WP. Among the 10 hospitalized case patients from AV and WP during 2006–2010, 
1 was <1 year old, 1 was 14 years old, and 8 were ≥20 years of age. None of the hospitalized 
case patients had been vaccinated. Only 1 of the hospitalized case patients had an 
immunocompromising condition. Five of the 10 hospitalized case patients had varicella-
related complications; 2 had pneumonia, and 3 had skin/soft tissue infections.
Between 2003 and 2006, 3 varicella outbreaks were reported from WP (2 in schools and 1 in 
a day care), and no outbreaks occurred after implementation of the 2-dose recommendation. 
There were 12 varicella outbreaks in AV during 2007–2010, compared with 47 during 
2003–2006 and 236 during 1995–1998 (P < .01; Table 3), representing 74.5% and 94.9% 
declines during 2007–2010 compared with 2003–2006 and 1995–1998, respectively. There 
were no outbreaks in AV reported in 2011. Overall, 66 (65%) outbreak-related case patients 
identified during 2007–2010 in AV had been vaccinated, all with 1 dose. A larger proportion 
of outbreak-related case patients during 2007–2010 had mild disease (<50 lesions) compared 
with earlier time periods.
In AV, starting in 2001, children entering kindergarten or entering California schools from 
out of state were required to have 1 dose of varicella vaccine or evidence of immunity. By 
school year 2010–2011, students in kindergarten through 10th grade were covered by the 1-
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dose requirement. In Los Angeles County, estimated 1-dose varicella vaccination coverage 
among 19- to 35-month-olds increased from 90.5% in 2006 to 95.1% in 2010. Two-dose 
varicella vaccination coverage among kindergarten students in an AV public school district 
(n = 2026) at the start of the 2009–2010 school year was 84%. Two-dose varicella 
vaccination coverage among Kaiser Permanente Southern California enrollees residing in 
AV was 76% among 4-year-olds, 98% among 5-year-olds, and 99% among 6-year-olds in 
2010.
In Philadelphia, school entry requirements for 1 dose of varicella vaccine were implemented 
in 2000 for kindergarten and 2001 for sixth grade with grades K through 12 covered by the 
2007–2008 school year. Two doses of varicella vaccine were required for students entering 
kindergarten and first grade in 2007–2008 and sixth grade in 2009–2010. One-dose varicella 
vaccination coverage among children 19 to 35 months of age was 92.7% to 94.6% during 
2006–2010. During 2007–2010, 2-dose varicella vaccine coverage among children aged 4 to 
6 years increased from 39% to 59%. By 2010, 2-dose varicella vaccine coverage rates 
among children aged 7 to 9 years and 10 to 12 years were 61% and 45%.
DISCUSSION
The United States transitioned from a 1-dose to a 2-dose varicella vaccination program for 
children in 2006 to further decrease varicella and its complications.8 The second dose of 
varicella vaccine was expected to provide higher vaccine efficacy and offer improved 
protection to the 15% to 20% of children who do not respond adequately to the first dose.19 
Declines in varicella incidence and outbreaks reported since 2006 through vaccine 
effectiveness studies and passive surveillance have provided early indications of the impact 
of the 2-dose varicella vaccination program.20–22 The substantial declines in varicella 
incidence and outbreaks we report on from these 2 active surveillance areas during the first 5 
years of the 2-dose varicella vaccination program provide additional evidence of the 
program’s sustained impact. Supporting the attribution of these declines in varicella 
incidence to the 2-dose vaccination program is the fact that the greatest declines in varicella 
incidence have been noted among children for whom the second dose was recommended. 
Declines in varicella incidence were seen across all age groups, including infants, who are 
not eligible for varicella vaccination, and adults, in whom vaccination levels are considered 
to be low, with a smaller proportion of cases among persons with immunocompromising 
conditions, providing evidence of the benefit of high levels of immunity in the population. 
Varicella-related hospitalizations in the active surveillance areas declined nearly 50% during 
the first 5 years of the 2-dose varicella vaccination program. With full implementation of the 
2-dose varicella vaccination program, it may be possible to eliminate the most severe 
outcomes of varicella.
Opportunities for further declines in varicella incidence remain; in 2010, 57% of cases 
among 4- to 14-year-olds occurred in children who had received 1 or no doses of varicella 
vaccine. Although data are limited, there does appear to have been rapid uptake of the 
second dose of varicella vaccine among elementary school–age children in the years 
immediately after it was recommended.18,20 However, challenges to ensuring protection of 
all children before they enter adolescence and adulthood remain. In 2011, an estimated 20% 
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of adolescents had never had varicella and had not received the second dose of varicella 
vaccine.23 Catch-up vaccination of children and adolescents who previously received 1 dose 
of varicella vaccine is recommended; providers should use all routine health care visits to 
ensure that all children without evidence of varicella immunity have received 2 doses of 
varicella vaccine.8
An important consideration in the adoption of a 2-dose varicella vaccination program in the 
United States was the burden posed by varicella outbreaks, which, although greatly reduced 
in number and size, continued to occur even in settings with high 1-dose varicella 
vaccination coverage.11,24,25 During 2007–2010, there were no outbreaks in WP. In addition 
to the school entry regulations for vaccination, Philadelphia Department of Public Health 
was extremely proactive in implementing prevention and control measures when notified of 
a case in a school or day care setting. In AV, the number of outbreaks during 2007–2010 
declined nearly fourfold compared with the last 4 years of the 1-dose varicella vaccination 
program. Although none of the outbreak-related cases identified in AV had received 2 doses 
of varicella vaccine, large outbreaks involving 2-dose vaccinees have been reported.26 
Investigating cases and outbreaks among 1- and 2-dose vaccinees who present with 
modified disease is challenging in that it can be difficult to distinguish mild breakthrough 
varicella from other causes of rash and collect adequate specimens from maculopapular 
lesions for laboratory testing.26 As the positive predictive value of clinical diagnosis 
declines, better laboratory tools, including alternative specimen types suitable for collection 
in outbreak investigations that commence after rash resolution, are needed.27 Going forward, 
clinician education on the growing importance of laboratory confirmation of varicella will 
be important to ensure appropriate implementation of varicella control strategies.
Although the proportion of varicella cases that occurred among vaccinees remained stable 
since implementation of the 2-dose varicella vaccination program, nearly half of them were 
among 2-dose vaccinees in 2010. Data on clinical characteristics of breakthrough varicella 
in 2-dose vaccinees are limited, although cases with >300 lesions have not been reported to 
date.20,28,29 From our data as well as from a prelicensure varicella vaccine efficacy study, no 
statistically significant differences in the clinical characteristics of breakthrough varicella 
between 1- and 2-dose vaccinees have been reported.28 It is unclear if breakthrough varicella 
severity is truly similar across 1- and 2-dose vaccinees or if only the more severe end of the 
clinical spectrum of 2-dose varicella is coming to medical attention. The extent to which 2-
dose breakthrough disease is contagious is not known, although it is likely to be mediated at 
least in part by the number of lesions as was demonstrated for 1-dose breakthrough 
varicella.30
A number of limitations to these data should be considered. Laboratory confirmation was 
not performed for all cases, and some cases clinically diagnosed as having varicella, 
especially breakthrough varicella, may not have had varicella. This would lead to an 
underestimation of declines in varicella. It is also possible that some varicella cases in the 
active surveillance areas did not come to medical attention, leading to an overestimation of 
declines in varicella incidence. Data sources for estimating 2-dose varicella vaccination 
coverage levels are limited; reliance on registry data may result in imprecise coverage 
estimates.
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The varicella vaccination program in the United States has resulted in dramatic declines in 
varicella incidence, hospitalizations, and deaths. Ongoing surveillance will be needed to 
describe more fully the impact of the routine 2-dose varicella vaccination program in the 
United States. Full implementation of varicella vaccination recommendations across all age 
groups, including adolescents, adults, and women postpartum, remains critically important 
for ensuring the greatest possible protection of susceptible individuals at risk for severe 
varicella disease.
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WHAT’S KNOWN ON THIS SUBJECT
The 1-dose childhood varicella vaccination program in the United States resulted in 
dramatic declines in varicella incidence, hospitalizations, and deaths. There is little 
information on the impact of the 2006 recommendation for 2-dose varicella vaccination 
of children on varicella epidemiology.
WHAT THIS STUDY ADDS
In the first 5 years of the 2-dose varicella vaccination program, declines in varicella 
incidence were seen in all age groups, including infants who are not eligible for varicella 
vaccination, providing evidence of the benefit of high population immunity.
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Varicella incidence: AV (Los Angeles County, CA) and WP (PA), 2000–2010.
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TABLE 2
Number of Lesions by Age Group and Vaccination Status of Case Patients by Age Group, AV (Los Angeles 
County, CA) and WP (PA), 2006–2010, n = 1216
No. of Lesions Vaccinated With 2 Doses, n (%) Vaccinated With 1 Dose, n (%) Unvaccinated, n (%)
1–3 y n = 1 n = 111 n = 43
 <50 lesions 1 (100) 81 (73.0) 21 (48.8)
 50–500 lesions 0 29 (26.1) 22 (51.2)
 >500 lesions 0 1 (0.9) 0
4–7 y n = 52 n = 196 n = 23
 <50 lesions 38 (73.1) 134 (68.4) 16 (69.6)
 50–500 lesions 14a (26.9) 62 (31.6) 6 (26.1)
 >500 lesions 0 0 1 (4.4)
8–14 y n = 36 n = 435 n = 136
 <50 lesions 23 (63.9) 299 (68.7) 47 (34.6)
 50–500 lesions 13a (36.1) 133 (30.6) 84 (61.8)
 >500 lesions 0 3 (0.7) 5 (3.7)
15–19 y n = 2 n = 18 n = 65
 <50 lesions 2 (100) 11 (61.1) 19 (29.2)
 50–500 lesions 0 7 (38.9) 40 (61.5)
 >500 lesions 0 0 6 (9.2)
≥20 y n = 0 n = 3 n = 95
 <50 lesions — 3 (100) 31 (32.6)
 50–500 lesions — 0 61 (64.2)
 >500 lesions — 0 3 (3.2)
a
None of the 2-dose breakthrough case patients had >250 lesions.
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